Penpulimab Biosimilar - Research Grade

In stock

Only %1 left

SKU

ICH5112

Add to Compare

Be the first to review this product

$315.00 - $19,890.00

Penpulimab Biosimilar - Research Grade

Endotoxin

<1EU/mg Determined by LAL gel clotting assay

Purity

≥95% monomer by analytical SEC, >95% by SDS Page

Species Reactivity

Human

Target

PD-1

Concentration

>1mg/ml

Isotype

Human IgG1 (L234A/L235A/G237A)-Kappa

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q15116

Shipping Conditions

Blue ice

Background

This product is an unconjugated, non-therapeutic recombinant analog of the anti-PD-1 antibody penpulimab, supplied for research use only. It is built around the human PD-1 (PDCD1) target and reproduces the antigen-binding specificity of the originator drug, allowing researchers to study PD-1 engagement, ligand blockade, and checkpoint biology without using clinical material. The molecule is formatted as a human IgG1 carrying L234A/L235A/G237A substitutions, an effector-attenuated ("silenced") Fc that minimises FcgammaR-mediated ADCC/ADCP and complement engagement, so activity in assays reflects PD-1 blockade rather than Fc effector function. It is useful as a positive control and reference reagent in binding, competition, and neutralisation assays, in receptor-occupancy and epitope work, in ADC or bispecific development pipelines, and in in-vitro and preclinical model systems. Manufactured as a low-endotoxin, RUO-grade protein and available in bulk milligram-to-gram quantities to support screening, assay standardisation, and process development. This is not the clinical drug and is not intended for human or veterinary use. PD-1 (programmed cell death protein 1; gene PDCD1, UniProt Q15116) is a type I transmembrane co-inhibitory receptor of the CD28/immunoglobulin superfamily, expressed on activated T cells, B cells, NK cells, and some myeloid populations. Its cytoplasmic tail contains an ITIM and an ITSM that, upon ligation, recruit the phosphatase SHP-2 to dephosphorylate proximal TCR and CD28 signalling components, dampening T-cell activation, proliferation, and cytokine production. PD-1 has two ligands, PD-L1 (CD274) and PD-L2 (PDCD1LG2), commonly upregulated in the tumour microenvironment and in chronic infection. Sustained PD-1/PD-L1 signalling drives T-cell exhaustion and peripheral tolerance. Antibodies that block the PD-1/PD-L1 axis relieve this inhibition, restoring effector T-cell function, which underpins the interest in PD-1 as an immune-checkpoint target for cancer immunotherapy research.

Other Names

CD279

Specificity

Detects human CD279

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Fc Modification

LALAGA

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.